Image

Thyroid Artery Embolization for the Treatment of Compressive Goiters.

Thyroid Artery Embolization for the Treatment of Compressive Goiters.

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.

Description

This study is a prospective interventional cohort study.

The prospective cohort setting allows us to evaluate the direct effect of TAE on a series of patients on a longer period and to strengthen the retrospective data previously documented in other studies.

Included patients will have compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter.

They have to be Ineligible for surgery/ablative treatments or preference for TAE over other treatments.

There is no comparative group in our study as it aims to prove that TAE is effective and safe in a "nonsurgical" population, a population in which other alternatives lack or are refused by the patient.

Our sampling method will be a non-probabilistic convenience sampling. Patients will be recruited in an outpatient setting by the patient's treating endocrinologist or otolaryngologist.

Eligibility

Inclusion Criteria:

  • Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND
  • Ineligible for surgery/ablative treatments or preference for TAE over other treatments AND
  • TiRADS category 1, 2, 3 or 4 AND
  • Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND
  • Patient at least 18 years old.

Exclusion Criteria:

  • Comorbidities precluding endovascular procedure OR
  • TiRADS category 5 OR
  • Bethesda categories IV, V, VI on biopsy OR
  • Refusal of the patient to participate OR
  • Uncontrolled severe hyperthyroidism OR
  • Minor patient.

Study details
    Thyroid Nodules

NCT07360587

Université de Sherbrooke

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.